A phase II study was designed to evaluate objective response rate and toxicity of fotemustine as single-drug chemotherapy in non-small-cell lung cancer. Eighty-seven patients with unresectable non-small-cell lung cancer took part in the study. Seventy-seven were evaluable for response. Of these, 60% had received prior chemotherapy and 74% had metastatic disease. Moreover, 22 patients had central nervous system metastases (of whom 12 were evaluable for this site). Chemotherapy is still an experimental treatment in a majority of patients with non-small-cell lung cancer (NSCLC) (Hansen, 1988) . Combinations of cisplatin and vinca alkaloids induce a survival improvement in unresectable NSCLC when compared with best supportive care. However, the ratio of the benefit in duration of survival to the benefit in quality of life (QL) might be suboptimal owing to the high frequency of toxic events induced by cisplatinbased regimens. Among NSCLC patients, those who relapse after first-line chemotherapy or those presenting central nervous system metastases are considered to have poor prognosis and are usually ineligible for cisplatin-based therapy. Thus, a search for new drugs is required in an attempt to obtain a survival advantage without inacceptable toxicity, particularly in patients with poor-prognosis NSCLC.
Chemotherapy is still an experimental treatment in a majority of patients with non-small-cell lung cancer (NSCLC) (Hansen, 1988) . Combinations of cisplatin and vinca alkaloids induce a survival improvement in unresectable NSCLC when compared with best supportive care. However, the ratio of the benefit in duration of survival to the benefit in quality of life (QL) might be suboptimal owing to the high frequency of toxic events induced by cisplatinbased regimens. Among NSCLC patients, those who relapse after first-line chemotherapy or those presenting central nervous system metastases are considered to have poor prognosis and are usually ineligible for cisplatin-based therapy. Thus, a search for new drugs is required in an attempt to obtain a survival advantage without inacceptable toxicity, particularly in patients with poor-prognosis NSCLC.
Fotemustine, a new amino acid phosphonate derivative of the nitrosourea group, has been recently introduced in the treatment of human solid malignancies (Avril et al., 1990; Jacquillat et al., 1990a) . This cytotoxic drug induced a 24% objective response (OR) rate in a phase II study of fotemustine as a single-drug therapy in disseminated malignant melanoma (Jacquillat et al., 1990a) , including patients with brain metastases (Jacquillat et al., 1990b) . This drug has also been reported to be active in primary brain tumours (Frenay et al., 1991) . In a previous phase II study, we tested fotemustine in the treatment of squamous cell carcinoma using the 100 mg m-2 dosage on a day 1, 8 and 15 regimen followed by a 5 week rest period, with maintenance therapy thereafter consisting of a course of 100 mg m-2 every 3 weeks (Le Chevalier et al., 1989 ). An OR rate of 12% was observed but the treatment was associated with a 30% grade IV thrombopenia toxicity. It has been observed, in a more recent study of fotemustine 100 mg m-2 in melanoma, that the day 1, day 8 schedule is well tolerated with a similar efficacy (Avril et al., 1990 We report herein a French multicentre phase II study on fotemustine on day 1 and day 8 in patients with poorprognosis advanced NSCLC.
Patients and methods

Eligibility criteria
Patients of both sexes with histologically proven and unresectable NSCLC were entered. Inclusion criteria were: age below 75 years; Karnofsky index > 60%; baseline leucocytes 4,000 ttl' or more, neutrophils 2,000 pl`' or more and platelets 150,000 l-1 or more; bilirubin, alkaline phosphatase, serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) lower than twice the normal upper limits; measurable or evaluable disease; and written informed consent. Staging was carried out by exhaustive procedure according to the fourth edition of the UICC-TNM classification and the American Thoracic Society map of regional pulmonary nodes (Tisi et al., 1982; Sobin et al., 1987) . Patients presenting central nervous system metastases were eligible, whereas patients for whom bone metastases were the only evaluable lesions were not included. Only evolutive lesions (i.e. lesions for which a progression before inclusion could be documented) were A QL index (Spitzer et al., 1984) was recorded at the time of inclusion and afterwards on days 8, 22, 36 and 43. In addition, we assessed five important somatic variables: appetite, body weight, pain, sleep and fatigue. At each reassessment, the variables were scored as follows: -1, 0 and +1 for impairment, stabilisation and improvement respectively. These variables were included in an original somatic scale consisting of the sum of the five scores.
Tumour response measurement Tumour response was assessed using the WHO response criteria (World Health Organization, 1979) . Indicator lesions were clearly defined at the time of inclusion and the technique used for measurement was also defined (usually CT scan). A complete response (CR) was defined as the complete disappearance of all lesions; a partial response (PR) was defined as > 50% reduction in the product of the two longest perpendicular diameters of the indicator lesion for measurable tumours, or an improvement > 50% for evaluable-only indicator lesions. A minor response (MR) was defined as a 25-49% decrease in the measurable indicator lesion in the product of the two longest perpendicular diameters of the indicator lesions, whereas stable disease (5) 16 (21) 57 (74) 19 (25) 46 (60) 21 (15) (SD) was defined as a less than 25% reduction and a less than 25% increase in this product. (median nadir day 36) and, to a minor extent, neutropenia. The incidence of grade III-IV thrombopenia was higher in pretreated patients than in non-pretreated ones (8% vs 26%, P <0.05), whereas neutropenia and leucopenia did not significantly differ. We observed no neutropenia-induced fever. Three patients required both red blood cell and platelet transfusions.
Gastrointestinal toxicity was moderate in as much as grade III nausea and vomiting was only reported in 3.7% of 129 analysed courses; and two patients had diarrhoea. Hepatic toxicity resulted in a moderate and reversible increase in SGPT, SGOT, bilirubin and alkaline phosphatase levels, and none of the patients experienced a grade IV toxicity or a clinical hepatic toxicity. Moreover, there was only one patient with a grade III increase in SGOT. In two cases biological adverse effects might possibly be related to treatment, whereas in the other instances liver metastases and/or pretreatment might be responsible for these biological modifications. There was no severe modification of renal function.
Survival
Median survival of the whole population was 20 weeks (range 2-111 + weeks; Figure 1 ). It did not significantly differ when pretreated patient survival was compared with other patient survival [median survival of 20 weeks (range 2-91 + weeks) vs 19 weeks (range 2-111) weeks respectively]. Moreover, the subgroup of patients with brain metastases had an identical survival rate. The probability of survival at 9 and 12 months was 29 and 14% respectively. At the time of reporting, seven patients had survived for more than 1 year. Their mean age was 57 years (range 38-73). All had a stage IV squamous cell carcinoma with a Karnofsky index of 80%. Four had received chemotherapy prior to entering this study and four had received brain radiation therapy for brain metastases. In these seven patients, induction chemotherapy using fotemustine resulted in a partial response in five cases and stabilisation in one, whereas the disease progressed in the remaining patient.
Quality of life QL index was reliable and fully analysed in 54 patients. The mean QL of the whole population decreased slightly during treatment when comparing day 0 with day 43. However, the relation of QL versus time was not significant (Figure 2 ; P = 0.09). QL index remained stable during the study period for patients with response or stabilisation, whereas it significantly decreased (P <0.001) in patients who experienced progression of the disease. The somatic scale was fully assessed in 60 patients (69%). This decreased significantly during the study duration (P = 0.001). However, in patients with response or stable disease the somatic scale did not vary according to time (Figure 3 ). Mean expanded on-study time was 97 days (range 3-385 days). Only five patients were admitted for treatment of a toxic event related to fotemustine. Twenty-nine patients (33%) were never hospitalised, even for fotemustine treatment. This subgroup and the entire population had a similar duration of on-study time (90 and 97 days respectively). . (Bunn, 1991; Donnadieu et at., 1991 (Pujol et at., 1990; Donnadieu et at., 1991) . Thus, in the setting of locally advanced NSCLC, the main goal is to improve the rate of cure by including chemotherapy in combined-modality treatments. On the other hand, metastatic NSCLC is mainly an incurable disease for which chemotherapy must reach the best therapeutic index, i.e. antineoplastic activity without unacceptable toxicity. The use of cisplatin-based combinations is unfortunately limited by the high incidence of digestive toxicity and by the ineligibility of patients with poor Karnofsky index and/or renal dysfunction. Thus, for these patients other treatment modalities must be considered. Finally, it is necessary to propose treatment to patients with an acceptable Karnofsky index but poor prognosis, i.e. patients who need a secondline treatment or patients presenting with brain metastases. For these patients the choice should be a compromise between potential benefit in survival and QL and decrease in hospitalisation and cost. However, until now, most of the new drugs have been investigated as first-line treatment, whereas others are inefficient as second-line therapy. Thus, new active drugs in patients with poor prognostic factors are needed because their treatment is a frequent problem in current practice.
The present study demonstrates the feasibility of a chemotherapy regimen consisting of fotemustine 100 mg m 2 administered on a day 1 and 8 schedule. It is noteworthy that the inclusion criteria of this trial matched the characteristics of the patient population admitted into our institutions, in particular pretreated patients or patients with central nervous system metastases. Both features, usually excluded from conventional chemotherapy trials, were eligible in this study and the results in these subgroups were good even though they were slightly lower than in other patients. Overall toxicity can be considered as mild to moderate and manageable. The low haematological toxicity, even in pretreated patients, and the low gastrointestinal, hepatic and renal toxicities make it possible to propose fotemustine as a treatment for poorprognosis NSCLC even though renal function is impaired. Of interest, there was no major modification of the QL index during the study and the somatic scale proposed by this study only decreased in patients who progressed during the treatment. Thus, fotemustine seems not to impair the QL.
To be considered as active, an antineoplastic drug must produce a response rate > 15% (Hansen, 1988) . Both response rate and response duration observed in this study were over this limit. Fotemustine had, therefore, a good therapeutic index in as much as the 17% OR rate is associated with neither life-threatening toxic events nor impairment of the QL and is an applicable treatment in poor-prognosis NSCLC. Our results deserve further evaluation of fotemustine in combination with other active drugs in NSCLC.
